Biểu đồ giá cổ phiếu PROK
PROK Tài chính
Prokidney Corp
$1.38
-1.42%
$-0.02
Khi đóng cửa: Aug 18, 16:00:00 GMT-4
$1.41
2.17%
$0.03
Phiên trước giờ: Aug 19, 04:31:42 GMT-4
Quay lại
Prokidney Corp (PROK) Tài chính
Thống kê chính
Giá đóng cửa trước
$1.4
Giá mở cửa
$1.39
Phạm vi ngày
$1.35 - $1.41
Phạm vi 52 tuần
$1.41 - $3.47
Khối lượng
1.0M
Khối lượng trung bình
1.0M
Tỷ suất cổ tức
--
EPS (TTM)
-0.53
Vốn hóa thị trường
$425.9M
PROK là gì?
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 231 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
